Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “GASTROINTESTINAL HORMONES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,801 records · Page 100Linked to original sources
PubMed2005

Corticotropin-releasing hormone receptor 1 antagonist blocks brain-gut activation induced by colonic distention in rats.

BACKGROUND & AIMS: The corticotropin-releasing hormone receptor 1 mediates stress-induced changes in colonic motor activity and emotion. We tested the hypothesis that pretreatment with JTC-017, a specific corticotropin-releasing hormone receptor 1 antagonist, blocks colorectal distention-induced hippocampal noradrenaline release and visceral perception in rats. We also investigated whether pretreatment with JTC-017 blocks acute or chronic colorectal distention-induced adrenocorticotropic hormone release, anxiety, and stress-induced changes in colonic motility. METHODS: Rats were pretreated intrahippocampally with alpha-helical corticotropin-releasing hormone (1.25 microg/kg; vehicle), a nonspecific corticotropin-releasing hormone receptor antagonist, or intraperitoneally with JTC-017 (10 mg/kg). Hippocampal noradrenaline release after microdialysis and the frequency of abdominal contractions were measured in response to acute colorectal distention. Plasma adrenocorticotropic hormone levels, anxiety-related behavior, and stress-induced changes in colonic motility were evaluated after acute or chronic colorectal distention followed by exposure to an elevated plus maze. RESULTS: Administration of alpha-helical corticotropin-releasing hormone or JTC-017 significantly attenuated hippocampal noradrenaline release and reduced the frequency of abdominal contractions induced by acute distention. In addition, JTC-017 significantly reduced plasma adrenocorticotropic hormone and anxiety after acute distention. After chronic distention, changes in plasma adrenocorticotropic hormone and anxiety were not significant because of habituation. In contrast, a significant increase in fecal pellet output during the elevated plus maze was observed after chronic distention. This increase in fecal pellet output was blocked by pretreatment with JTC-017. CONCLUSIONS: Our results suggest that JTC-017, a specific corticotropin-releasing hormone receptor 1 antagonist, attenuates hippocampal noradrenaline release, visceral perception, adrenocorticotropic hormone release, and anxiety after acute colorectal distention in rats. In addition, JTC-017 blocks stress-induced changes in colonic motility after chronic colorectal distention in rats.

Abdominal Muscles↗
PubMed1961

Immunological studies of gastrin.

Hog gastrin prepared by the Gregory method stimulates antibody production in rabbits. Rabbit anti-hog gastrin serum which was reacted with hog, dog, and human gastrins in vitro caused reduction of their gastric stimulatory effect, indicating a biological cross reaction among these species.

Animals↗
PubMed2006

Emerging therapeutic strategies for obesity.

The rising tide of obesity is one of the most pressing health issues of our time, yet existing medicines to combat the problem are disappointingly limited in number and effectiveness. Fortunately, a recent burgeoning of mechanistic insights into the neuroendocrine regulation of body weight provides an expanding list of molecular targets for novel, rationally designed antiobesity pharmaceuticals. In this review, we articulate a set of conceptual principles that we feel could help prioritize among these molecules in the development of obesity therapeutics, based on an understanding of energy homeostasis. We focus primarily on central targets, highlighting selected strategies to stimulate endogenous catabolic signals or inhibit anabolic signals. Examples of the former approach include methods to enhance central leptin signaling through intranasal leptin delivery, use of superpotent leptin-receptor agonists, and mechanisms to increase leptin sensitivity by manipulating SOCS-3, PTP-1B, ciliary neurotrophic factor, or simply by first losing weight with traditional interventions. Techniques to augment signaling by neurochemical mediators of leptin action that lie downstream of at least some levels of obesity-associated leptin resistance include activation of melanocortin receptors or 5-HT2C and 5-HT1B receptors. We also describe strategies to inhibit anabolic molecules, such as neuropeptide Y, melanin-concentrating hormone, ghrelin, and endocannabinoids. Modulation of gastrointestinal satiation and hunger signals is discussed as well. As scientists continue to provide fundamental insights into the mechanisms governing body weight, the future looks bright for development of new and better antiobesity medications to be used with diet and exercise to facilitate substantial weight loss.

Anti-Obesity Agents↗
PubMed1981

Immunological evidence for the occurrence of luteinizing hormone-releasing factor and the alpha-subunit of glycoprotein hormones in carcinoid tumors.

The immunoperoxidase technique was used to identify LRF and glycoprotein hormones or their subunits in 22 carcinoid tumors of various origins. All tumors were positive for both LRF and the alpha-subunit, whereas stainings with antisera against the beta-subunits of CG, LH, FSH, and TSH were negative. The binding of LRF and the alpha-subunit within the same malignant tissue raises the possibility of a functional relationship between the two.

Bronchial Neoplasms↗
PubMed1979

Histaminergic involvement in thyrotropin-releasing hormone stimulation of antral tissue in the rat.

The mechanism of action of thyrotropin-releasing hormone on antral motility was investigated in vitro. With the recent detection of thyrotropin-releasing hormone in gastrointestinal tissue, the possibility exists that the peptide may play a physiologic role in gastrointestinal motility. Results indicate that the hormone stimulates antral motility through a non-cholinergic excitatory pathway based on the inability of the muscarinic antagonist, atropine, to block the response. A histaminergic pathway is an attractive possibility to explain the excitatory response, because both pyrilamine and cimetidine inhibit the thyrotropin-releasing hormone induced response and the peptide has no further influence on antral motility after the tissue is exposed to a supramaximal concentration of histamine.

Animals↗

Refine your search to explore more results.